Amphastar Pharmaceuticals, Inc. $AMPH Stake Increased by Rhumbline Advisers

Rhumbline Advisers grew its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 88,958 shares of the company’s stock after acquiring an additional 1,631 shares during the period. Rhumbline Advisers owned 0.19% of Amphastar Pharmaceuticals worth $2,579,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AMPH. Intech Investment Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 43.0% in the 1st quarter. Intech Investment Management LLC now owns 60,289 shares of the company’s stock valued at $1,748,000 after purchasing an additional 18,133 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 238.5% in the 1st quarter. Millennium Management LLC now owns 868,551 shares of the company’s stock valued at $25,179,000 after purchasing an additional 611,995 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after purchasing an additional 613 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 82.0% in the 1st quarter. AQR Capital Management LLC now owns 53,638 shares of the company’s stock valued at $1,555,000 after purchasing an additional 24,167 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at $766,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of research analyst reports. Bank of America boosted their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. Piper Sandler cut their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research report on Friday, August 8th. Finally, Needham & Company LLC raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $31.60.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $27.00 on Wednesday. The stock has a market cap of $1.26 billion, a P/E ratio of 10.11 and a beta of 0.80. The company’s 50-day simple moving average is $25.93 and its 200 day simple moving average is $25.57. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $53.96.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.